GlassScriptPhysician profile
Sharon Messics
NPI 1619993474
$6,432.03
in general payments reported to CMS, 2019-2025
42 companies · $1,265 in 2025
The $1,265 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $731 · 2020: $416 · 2021: $951 · 2022: $787 · 2023: $1,036 · 2024: $1,246 · 2025: $1,265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,002 · Gift: $350 · Consulting Fee: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,001.67 |
| Gift | $350.00 |
| Consulting Fee | $195.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $560.47 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $548.34 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $512.86 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $443.74 | 2019-2025 | Gardasil 9, Verquvo, Capvaxive |
| Novo Nordisk INC | $421.60 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $356.87 | 2021-2025 | |
| Sanofi US Services INC. | $350.00 | 2021 | |
| Celltrion, INC. | $350.00 | 2025 | Stoboclo |
| Glaxosmithkline, LLC. | $325.19 | 2021-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $240.00 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $234.75 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $228.67 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.96 | 2019-2025 | Jardiance |
| Amgen INC. | $178.73 | 2019-2024 | Prolia, Evenity |
| Abbott Laboratories | $146.21 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $127.59 | 2022-2025 | Vyepti, Rexulti |
| Janssen Pharmaceuticals, INC | $126.35 | 2020-2024 | Xarelto |
| Astellas Pharma US INC | $95.83 | 2024-2025 | Veozah |
| Dexcom, INC. | $94.96 | 2024-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.72 | 2024-2025 | Xifaxan |
| Corium, LLC | $69.67 | 2022-2023 | Azstarys |
| Phathom Pharmaceuticals, INC. | $68.93 | 2024-2025 | Voquezna |
| Allergan, INC. | $61.42 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $57.52 | 2022 | |
| Vertos Medical, INC. | $55.99 | 2024 | Mild Device Kit |
| Dynavax Technologies Corporation | $54.41 | 2022-2024 | Heplisav-B |
| Sanofi Pasteur INC. | $52.90 | 2021-2023 | |
| Corcept Therapeutics | $47.99 | 2025 | Korlym |
| Organon LLC | $44.23 | 2021-2023 | Nexplanon |
| Sumitomo Pharma America, INC. | $37.43 | 2025 | Gemtesa |
| Ultragenyx Pharmaceutical INC. | $36.18 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $32.07 | 2022-2023 | Abilify Maintena, Rexulti |
| Bausch Health US, LLC | $29.00 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $25.81 | 2021 | |
| Ironshore Pharmaceuticals INC. | $23.36 | 2023 | Jornay Pm |
| Xeris Pharmaceuticals, INC. | $22.78 | 2023 | Gvoke Hypopen |
| Amarin Pharma, INC. | $21.52 | 2022 | |
| Idorsia Pharmaceuticals US INC | $17.82 | 2024 | Quviviq |
| Medtronic, INC. | $17.62 | 2023 | Closurefast |
| Takeda Pharmaceuticals U.S.A., INC. | $16.07 | 2019 | |
| Exact Sciences Corporation | $14.58 | 2025 | Cologuard Collection Kit |
| Genentech USA, INC. | $13.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Messics listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.